CXCR4 and neoplasm: Targeting these paracrine pathways—such as IL-6 or CXCR4 inhibitors—offers promising therapeutic potential, particularly when combined with standard chemotherapies or immune checkpoint inhibitors.248 A more mechanistic understanding of CSC–TME interactions is essential for developing strategies that disrupt the supportive stromal niche and prevent tumor relapse.